Metabolism

STEP-HFpEF: Semaglutide Improves NYHA Functional Class in Obesity-Related HFpEF

STEP-HFpEF NT-proBNP Analysis: Greater Benefit with Higher Baseline Cardiac Stress

Semaglutide + Empagliflozin for NAFLD in T2D

STEP-HFpEF Pooled Analysis: Semaglutide Improves Symptoms, Function, and Inflammation in Obesity-HFpEF

Semaglutide and Obesity-Related Heart Failure

Tirzepatide Phase 1 Trial

A phase 1 clamp trial shows tirzepatide improves beta-cell function and insulin sensitivity more than semaglutide, explaining its glucose-lowering. PICO summary and commentary.

Semaglutide vs Canagliflozin for Body Composition in T2D: Fat Loss Similar Despite Greater Weight Loss with GLP-1 RA

Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients

In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.

Liraglutide’s Efficacy in Children Aged 6-12

In children aged 6 to

Tirzepatide for Obstructive Sleep Apnea: Phase 3 Trial Shows 59% Reduction in AHI

In adults with moderate-to-severe obstructive sleep apnoea (OSA) and obesity, tirzepatide significantly reduced the apnea-hypopnea index (AHI) and body weight compared to placebo, with notable improvements in sleep-related outcomes and cardiovascular risk factors, albeit with increased gastrointestinal side effects.